MedWatch

Novo Nordisk: no outsourcing of clinical research

Pharmaceutical companies all over the world are outsourcing more and more of their clinical research – but not Novo Nordisk. The Danish pharma giant is not convinced that the external research companies add anything to the bottom line.

Foto: -

The Danish diabetes group avoids one of the major trends in the global Big Pharma industry at the moment. Rather than outsourcing clinical research to Clinical Research Organizations (CROs) Novo Nordisk will rely on its own organization.

“There is a strong tendency towards outsourcing and viewing clinical trials as something to be purchased elsewhere. We don’t have a lot of faith in that strategy,” Head of Development for Novo Nordisk, Peter Kristensen, tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier